BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16450393)

  • 1. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
    Cheung IY; Vickers A; Cheung NK
    Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
    Cheung IY; Feng Y; Vickers A; Gerald W; Cheung NK
    J Mol Diagn; 2007 Apr; 9(2):237-41. PubMed ID: 17384216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
    Cheung IY; Cheung NK
    Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
    Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
    Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
    Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
    Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of polysialyltransferase expression during hippocampus development: Implications for neuronal survival.
    Brocco M; Pollevick GD; Frasch AC
    J Neurosci Res; 2003 Dec; 74(5):744-53. PubMed ID: 14635225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Cheung NK
    J Clin Oncol; 2003 Oct; 21(20):3853-8. PubMed ID: 14551304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
    Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
    Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GD2 synthase: a new molecular marker for detecting neuroblastoma.
    Lo Piccolo MS; Cheung NK; Cheung IY
    Cancer; 2001 Aug; 92(4):924-31. PubMed ID: 11550167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
    Corrias MV; Haupt R; Carlini B; Cappelli E; Giardino S; Tripodi G; Tonini GP; Garaventa A; Pistoia V; Pistorio A
    Pediatr Blood Cancer; 2012 Jan; 58(1):43-9. PubMed ID: 21254375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.
    Fest S; Soldati R; Christiansen NM; Zenclussen ML; Kilz J; Berger E; Starke S; Lode HN; Engel C; Zenclussen AC; Christiansen H
    Int J Cancer; 2016 Apr; 138(8):2030-42. PubMed ID: 26595750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
    Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
    Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
    Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
    J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
    Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
    J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
    Cheung IY; Feng Y; Gerald W; Cheung NK
    Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.